Achieving robust somatic mutation detection with deep learning models derived from reference data sets of a cancer sample
Open accessAbstract
BACKGROUND: Accurate detection of somatic mutations is challenging but critical in understanding cancer formation, progression, and treatment. We recently proposed NeuSomatic, the first deep convolutional neural network-based somatic mutation detection approach, and demonstrated performance advantages on in silico data. RESULTS: In this study, we use the first comprehensive and well-characterized somatic reference data sets from the SEQC2 consortium to investigate best practices for using a deep learning framework in cancer mutation detection. Using the high-confidence somatic mutations established for a cancer cell line by the consortium, we identify the best strategy for building robust models on multiple data sets derived from samples representing real scenarios, for example, a model trained on a combination of real and spike-in mutations had the highest average performance. CONCLUSIONS: The strategy identified in our study achieved high robustness across multiple sequencing technologies for fresh and FFPE DNA input, varying tumor/normal purities, and different coverages, with significant superiority over conventional detection approaches in general, as well as in challenging situations such as low coverage, low variant allele frequency, DNA damage, and difficult genomic regions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
AI is used in nearly every step of next-generation sequencing processing and interpretation, including mutation identification, artifact filtering, and driver gene identification.
“This includes the use of AI in nearly every step of next-generation sequencing (NGS) processing and interpretation, including mutation identification (122, 123), artifact filtering (124), and driver gene identification (125).”
From Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions (2024) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 25 · Cited by 27
Research works printed but not linked: 1
- [25]Xiao, W. et. al., Somatic Mutation Working Group of Sequence Quality Control Phase 2 (SEQC2) Consortium to develop paired tumor/normal reference samples/materials for clinical sequencing, PRJNA489865, BioProject, https://www.ncbi.nlm.nih.gov/bioproject/PRJNA489865 (2018).
- Authors
- Sahraeian, S. M. E., Fang, L. T., Karagiannis, K., Moos, M., Smith, S., Santana-Quintero, L., Xiao, C., Colgan, M., Hong, H., Mohiyuddin, M., & Xiao, W.
- Affiliations
- Center for Biologics Evaluation and Research (US)
- National Institutes of Health (US)
- United States Food and Drug Administration (US)
- National Center for Toxicological Research (US)
- Corresponding author
- Xiao, Wenming
- ORCID
- Venue
- Genome biology
- Published
- 2022-01-07
- Volume
- 23
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1465-6906 (ISSN-L)
- 1474-760X
- PMC
- PMC8740374
- OpenAlex
- W4206815942
- Cited by
- 27
- References
- 25
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 8 · 2023: 7 · 2022: 3
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Genome biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Oxford
- National Institutes of Health
- National Cancer Institute (HHSN261201400008C, HHSN261201500003I, HHSN261201500003C)
- Division of Cancer Epidemiology and Genetics, National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- somatic mutation detection, convolutional neural networks, cancer cell lines, model robustness, FFPE DNA, tumor purity, sequencing depth, variant allele frequency, DNA damage, sequencing platform comparison
- MeSH terms
- Deep Learning, Humans, Mutation, Neoplasms, Neural Networks, Computer, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review